An FDA advisory panel narrowly recommended expanding compounding access for certain unapproved peptides, despite limited evidence and safety concerns raised by scientists. The Pharmacy Compounding Advisory Committee’s discussion sets up an FDA decision that could broaden the Section 503A Bulk Drug Substances List for additional peptides. The review is politically and clinically charged, with panelists weighing a pathway that would allow compounded pharmacies to manufacture substances lacking full approval and comprehensive clinical evidence. FDA staff and expert arguments emphasized that this could end-run the standard safety and effectiveness framework. The panel vote is non-binding, but it signals that the regulatory outcome may swing toward broader availability, changing how patients and clinicians interact with compounded peptide therapies. In the background, compounding policy is being watched closely by both patient communities and established drug developers because expanded access could accelerate market adoption of substances outside approved-label settings.